Barrick Mining Corporation Stock Price, News & Analysis

Helzberg (NYSE:A) will open redesigned stores in New York and Dallas in November 2025, unveiling next‑generation brick-and-mortar concepts that combine digital discovery with hands-on craftsmanship. The new stores feature an interactive custom bar, a visible jeweler's workshop, a larger diamond carat-weight assortment in engagement rings and wedding bands, and an expanded Luxe Jewelry collection.

A company consumer study found 83% of couples say the ability to purchase in-store is important, nearly three in five plan to consult a jeweler and buy in person, 47% rate ring customization as very important, and 76% would invest more in a custom design. Helzberg also highlights digital support via its Love & Marriage Studio for pre-visit education and inspiration.

Metsera (NASDAQ: B) announced its board has declared an amended acquisition proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal values Metsera at up to $86.20 per share (~$10.0B), including an immediate cash payment/dividend of $62.20 per share and a second-step contingent value right (CVR) of up to $24.00 per share. Metsera notified Pfizer, triggering a two-business-day negotiation period under the Pfizer Merger Agreement.

Metsera (NASDAQ: B) announced that its board has declared an amended proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer on Nov 4, 2025. The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share (~$10.0 billion) via a two-step structure: an immediate $62.20 per share cash payment plus non-voting preferred stock, followed by a dividend of $62.20, and a contingent value right (CVR) worth up to $24.00 per share upon regulatory and development milestones.

Metsera notified Pfizer, triggering a two-business-day period for Pfizer to propose adjustments under the Pfizer Merger Agreement; Pfizer previously revised its proposal to $60.00 upfront + up to $10.00 CVR.

BioArctic (Nasdaq Stockholm: B) will publish its third quarter report for July–September 2025 on Thursday, 13 November 2025 at 08:00 CET. An English-language audiocast with teleconference will follow the report on 13 November 2025 at 09:30 CET, where CEO Gunilla Osswald and CFO Anders Martin-Löf with colleagues will present the report and hold a Q&A.

Investors, analysts and media can join via webcast (written questions) or teleconference (verbal questions) after registration. The webcast will be available on demand on BioArctic's investor website. Contact: Oskar Bosson, VP Communications and Investor Relations.

Crawford & Company (NYSE: CRD-A, CRD-B) announced that on October 30, 2025 its Board authorized an additional 2.0 million shares under its existing share repurchase program and extended the program termination to December 31, 2027. The repurchase program, originally approved November 4, 2021 and increased February 10, 2022, had authorized up to an aggregate of seven million common shares; as of October 30, 2025 only 634,920 shares remained under that authorization. Repurchases may occur in the open market or via privately negotiated transactions and are discretionary. The Board also declared a quarterly dividend of $0.075 per share, payable December 5, 2025 to shareholders of record as of November 19, 2025.

Metsera (NASDAQ: B) announced its board has declared an unsolicited proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal would pay $56.50 per share in cash at signing, issue Novo non-voting preferred stock representing 50% of Metsera's share capital, then pay a CVR up to $21.25 per share upon milestones, valuing Metsera at up to $77.75 per share (~$9 billion).

The proposal represents an approximate 133% premium to Metsera's close on Sept 19, 2025. Metsera notified Pfizer, triggering a four-business-day period for Pfizer to propose adjustments; Pfizer disputes Metsera's right to deliver the notice. The Pfizer merger agreement remains in effect and Metsera's board reaffirmed its recommendation to approve the Pfizer transaction; no shareholder action is required now.

Hexagon (B) and Management Controls announced general availability of the EcoSys + myTrack Connector, integrating EcoSys Enterprise Project Performance with MCi myTrack contractor data via EcoSys Connect.

The connector delivers real-time, verified contractor actuals into EcoSys—including labor, equipment, and materials—for STOs and capital projects, automating contractor cost flows, eliminating manual reconciliations, enabling force reporting, improving forecasting accuracy, accelerating project closeouts, and reducing financial leakage. Implementation support is available worldwide in partnership with FTI Consulting.

BioArctic (NASDAQ: B) announced that partner Eisai received a Notice of Compliance with Conditions (NOC/c) from Health Canada for Leqembi (lecanemab) on October 27, 2025, authorizing use in adults with early Alzheimer’s disease who are ApoE ε4 non-carriers or heterozygotes and have confirmed amyloid pathology.

Leqembi is described as the first treatment targeting an underlying cause of early AD and shown in the Phase 3 Clarity AD study to slow cognitive and functional decline; it is approved in 51 countries and regions. The Canadian authorization is conditional pending confirmatory trials and Eisai will submit real-world clinical assessment data. BioArctic retains Nordic commercialization rights and plans joint regional commercialization with Eisai.

BioArctic (Nasdaq Stockholm: BIOA) announced on October 14, 2025 that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease, was selected by TIME as one of the Best Inventions of 2025 in the Medical and Healthcare category.

The selection recognizes the product's innovation and potential impact. Leqembi was developed in collaboration with Eisai, which leads clinical development, regulatory approvals and global commercialization. BioArctic retains rights to commercialize Leqembi in the Nordic region together with Eisai. Prescribing information in the US includes a Boxed WARNING.